COVID-19 therapy: What weapons do we bring into battle?

Almeida, Sinara Mônica Vitalino de; Soares, José Cleberson Santos; Santos, Keriolaine Lima dos; Alves, Josival Emanuel Ferreira; Ribeiro, Amélia Galdino; Jacob, Iris Trindade Tenório; Ferreira, Cindy Juliane da Silva; Santos, Jéssica Celerino dos; Oliveira, Jamerson Ferreira de; Carvalho, Luiz Bezerra de; Lima, Maria do Carmo Alves de

doi:10.1016/j.bmc.2020.115757

Cited by 24 publications

(23 citation statements)

References 328 publications

(450 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Urgent COVID-19 therapeutic options are desired by the community ( de Almeida et al, 2020 ). In this regard, based on previous therapeutic experience with SARS-CoV and MERS-CoV, there has been a substantial inquisitiveness in the repurposing of approved antiviral drugs (for example, drugs used to treat HIV, HBV, HCV, filoviruses, and influenza) and development of new drugs for COVID-19 ( Artese et al, 2020 ; Liu and Wang, 2020 ).…”

Section: Discussion and Perspectivesmentioning

confidence: 99%

Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease

et al. 2021

View full text Add to dashboard Cite

Effective, safe, and pharmacokinetically suitable drugs are urgently needed to curb the ongoing COVID-19 pandemic. The main protease or 3C-like protease (Mpro or 3CLpro) of SARS-CoV-2 is considered an important target to formulate potent drugs corresponding to its crucial role in virus replication and maturation in addition to its relatively conserved active site. Promising baseline data on the potency and safety of drugs targeting SARS-CoV-2 Mpro are currently available. However, preclinical and clinical data on the pharmacokinetic profiles of these drugs are very limited. This review discusses the potency, safety, and pharmacokinetic profiles of potential inhibitors of SARS-CoV-2 Mpro and forward directions on the development of future studies focusing on COVID-19 therapeutics.

show abstract

Section: Discussion and Perspectivesmentioning

confidence: 99%

Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…CsA has immunosuppressive and antiinflammatory properties attributable to its ability to inhibit the transcription of genes required for T cell proliferation (including genes for IL-2). 105 , 106 On the other hand, IL-2 is reported as a potential trigger of the cytokine storm in severe COVID-19. 107 SARS-CoV nsp1 induces the expression of IL-2 via activation of nuclear factor of activated T cell.…”

Section: Repurposing Of Dermatologic Medications To Treat Covid-19mentioning

confidence: 99%

Drug repurposing of dermatologic medications to treat coronavirus disease 2019: Science or fiction?

Mateeva

Drenovska

2021

Clinics in Dermatology

View full text Add to dashboard Cite

No pharmaceutical products have been demonstrated to be safe and effective to specifically treat coronavirus disease 2019 (COVID-19); therefore, the therapy administered to infected patients remains symptomatic and empiric. Alongside the development of new, often high-cost drugs, a different tactic is being applied in parallel, investigating long-established, inexpensive medications originally designed for a variety of diseases to study their potential in treating COVID-19. The skin is the largest organ of the human body. With more than 3,000 skin conditions identified, the specialty of dermatology offers a rich armamentarium of systemic therapeutic agents aimed to treat the various chronic immunologically mediated, metabolic, infectious, occupational, inherited, or paraneoplastic dermatoses. Dermatologists have extensive experience with many drugs that have demonstrated promising in vitro antiviral action (directly targeting the viral replication). Many of these drugs have been used as nonspecific immunosuppressive strategies, such as glucocorticoids, synthetic antimalarials, colchicine, or other immunomodulators, and a number of targeted therapeutics have been directed at controlling hyperinflammatory processes similar to the “cytokine storm” associated with COVID-19 infection. We discuss several dermatologic drugs that have already been used or may have a promising role in the treatment of COVID-19.

show abstract

“…Acyclovir [6] Arbidol [5] Boceprevir [18] Chloroquine [5] Darunavir [5] Elvitegravir [17] Ganciclovir [5] Hydroxychloroquine [5] K-12 [16] Lopinavir [5] Favipiravir [5] Oseltamivir [5] Ribavirin [5] Remdesivir [5] Ritonavir [5] In this study are investigated five SARS-CoV-2 targets: main protease (PD ID: 6W63, PD ID: 6WNP), spike glycoprotein (closed state) (PD ID: 6VXX), chimeric receptor-binding domain complexed with its receptor human ACE2 (PD ID: 6VW1), RNA-dependent RNA polymerase (PD ID: 6M71) and 3CL protease (3CL pro) (PD ID: 6M2N).…”

Section: Molecular Docking Studiesmentioning

confidence: 99%

“…To develop new drugs with antiviral activity, the concern of many research groups is focused on the repositioning of already approved drugs [3][4][5][6] and the fastest way is to find potential drugs by molecular docking studies [7][8][9][10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Molecular Docking Studies on Synthetic Therapeutic Agents for COVID-19

Pintilie

Tănase

Mohapatra³

2020

The 24th International Electronic Conference on Synthetic Organic Chemistry

View full text Add to dashboard Cite

Coronavirus disease (COVID-19) is an infectious disease caused by coronavirus 2 (SARS CoV-2) who have been detected for the first time in Wuhan China in December 2019. The rapid spread of this highly contagious and pathogenic virus led to the declaration of the pandemic by the World Health Organization (WHO) on March 11, 2020. In these conditions, the discovery of new antiviral agents is extremely important. For the development of the anti-SARS-CoV-2 drugs, the fastest way is to find potential molecules from the marketed drugs by molecular docking studies.

show abstract

COVID-19 therapy: What weapons do we bring into battle?

Abstract: Graphical abstract

Cited by 24 publications

References 328 publications

Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease

Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease

Drug repurposing of dermatologic medications to treat coronavirus disease 2019: Science or fiction?

Molecular Docking Studies on Synthetic Therapeutic Agents for COVID-19

Contact Info

Product

Resources

About